[Systemic chemotherapy for bladder cancer: news in 2009].
This review summarizes the results of first-line and second-line systemic chemotherapy for advanced urothelial carcinoma as well as data from adjuvant and neoadjuvant trials for locally advanced bladder cancer. Whereas conventional systemic chemotherapy prevailed for over two decades, targeted therapeutics have been introduced to treat urothelial cancer during recent years. As in other tumor entities, molecular profiling will presumably emerge in the future as a means to tailor individual therapy.
Retz
M
M
Urologische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität, München, Deutschland. AUO@MeckEvidence.de
Gschwend
J E
JE
Lehmann
J
J
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D019317:Evidence-Based Medicine; D006801:Humans; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents